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Hepatocyte-specific Smad7 expression attenuates
TGF-beta-mediated fibrogenesis and protects against liver
damage
Abstract
The profibrogenic role of transforming growth factor (TGF)-beta in liver has mostly been attributed to
hepatic stellate cell activation and excess matrix synthesis. Hepatocytes are believed to contribute to
increased rates of apoptosis. METHODS: Primary hepatocyte outgrowths and AML12 cells were used
as an in vitro model to detect TGF-beta effects on the cellular phenotype and expression profile.
Furthermore, a transgenic mouse model was used to determine the outcome of hepatocyte-specific
Smad7 expression on fibrogenesis following CCl(4)-dependent damage. Samples from patients with
chronic liver diseases were assessed for (partial) epithelial-to-mesenchymal transition (EMT) in
hepatocytes. RESULTS: In primary cell cultures and in vivo, the majority of hepatocytes survive despite
activated TGF-beta signaling. These cells display phenotypic changes and express proteins characteristic
for (partial) EMT and fibrogenesis. Experimental expression of Smad7 in hepatocytes of mice
attenuated TGF-beta signaling and EMT, resulted in less accumulation of interstitial collagens, and
improved CCl(4)-provoked liver damage and fibrosis scores compared with controls. CONCLUSIONS:
The data indicate that hepatocytes undergo TGF-beta-dependent EMT-like phenotypic changes and
actively participate in fibrogenesis. Furthermore, ablation of TGF-beta signaling specifically in this cell
type is sufficient to blunt the fibrogenic response.
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i.p., intraperitoneal 
I-Smads, inhibitory Smads 
LPS, lipopolysaccharide 
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SMA, smooth muscle actin 
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Abstract 
Background & Aims: The profibrogenic role of TGF-β in liver has mostly been 
attributed to hepatic stellate cell activation and excess matrix synthesis. 
Hepatocytes are believed to contribute with increased apoptosis rates. 
 
Methods: Primary hepatocyte outgrowths and AML12 cells were used as in 
vitro model to detect TGF-β effects on the cellular phenotype and expression 
profile. Furthermore, a transgenic mouse model was used to determine the 
outcome of hepatocyte-specific Smad7 expression on fibrogenesis following 
CCl4-dependent damage. Samples from patients with chronic liver diseases 
were assessed for (partial) EMT in hepatocytes. 
 
Results: In primary cell cultures and in vivo, the majority of hepatocytes 
survive despite activated TGF-β signaling. These cells display phenotypic 
changes and express proteins characteristic for (partial) epithelial 
mesenchymal transition (EMT) and fibrogenesis.  
Experimental expression of Smad7 in hepatocytes of mice attenuated TGF-β 
signaling and EMT, resulted in less accumulation of interstitial collagens, and 
improved CCl4 provoked liver damage and fibrosis scores compared to 
controls. 
 
Conclusions: The data indicate that hepatocytes undergo TGF-β-dependent 
EMT-like phenotypic changes and actively participate in fibrogenesis. 
Furthermore, ablation of TGF-β signaling specifically in this cell type is 
sufficient to blunt the fibrogenic response.  
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Introduction  
 
Fibroproliferative diseases are a leading cause of morbidity and mortality. All 
tissues and organ systems may be affected following inciting, mostly chronic 
damage 1. Fibrosis is comparable with a wound-healing response being out of 
control. Repair mechanisms aim at the replacement of injured cells, however 
contrary to the pure regeneration of tissue in fibroplasia, connective tissue 
substitutes normal parenchyma. The ultimate result is organ failure. In the 
liver, the final common pathway is cirrhosis, characterized by accumulation 
of fibrillar interstitial collagens type I and III, liver failure and portal 
hypertension. Striking increases in our understanding of the pathogenesis of 
liver fibrosis, with respect to its potential evolution and natural progression, 
include the identification of the main cellular effectors, key cytokines 
regulating the fibrotic process, and determinants of ECM turnover. 
Most recent work regarding liver fibrosis centers around the myofibroblast as 
pivotal cell type, due to its contractile nature and synthesis repertoire 2. The 
sources of myofibroblasts are still matter of discussions. Undisputedly, a 
“myofibroblast” phenotype is observed with hepatic stellate cells (HSCs) after 
exposure to profibrogenic cytokines. In addition to HSCs, myofibroblasts can 
be derived from local mesenchymal cells recruited from the bone marrow 
(where they are known as fibrocytes), or could derive from other cellular 
sources by epithelial mesenchymal transition (EMT), a physiologic process in 
embryogenesis and of relevance for cancerous cell transformation 3. Current 
concepts envision activated HSCs as crucial pro-fibrogenic source, while the 
majority of hepatocytes are thought to undergo necrosis or apoptosis, 
thereby providing space for proliferating cells. Besides the resident hepatic 
cells, infiltrating neutrophils, macrophages, T- and B- cells, and eosinophils 
participate in the inflammatory response and may perpetuate the damage, 
whereby activated macrophages and neutrophils clean up tissue debris, dead 
cells and invading organisms 4.  
Transforming growth factor (TGF)-β is recognized as major pro-fibrogenic 
cytokine. Signal transducing molecules linked to TGF-β stimulation are the 
Smad proteins. Upon ligand binding to the cell surface, the activated 
receptor complex phosphorylates receptor Smads (R-Smads), which then 
associate with Smad4, translocate into the nucleus and regulate expression 
of target genes 5. R-Smad signaling is limited by the inhibitory effects of I-
Smads6 and 7. 
Deregulated TGF-β signaling is implicated in multiple developmental 
disorders and various human diseases including cancer and autoimmune 
illnesses 6. Its overexpression is linked to liver fibrosis in diverse animal 
models 7 and in human patients with chronic liver diseases 8. TGF-β crucially 
regulates ECM deposition by controlling the expression of ECM network 
components such as fibrillar collagens and fibronectin, ECM-degrading 
protease inhibitors, such as plasminogen activator inhibitor (PAI-1) and 
tissue inhibitors of matrix metalloproteases (TIMPs). It’s activity is strongly 
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induced during chronic liver damage with links between TGF-β and CTGF in 
the HSC activation process 9. 
The only available treatment for liver cirrhosis is transplantation with the 
drawback of organ shortage. Preventive antifibrotic therapies are therefore 
highly needed. Various experimental approaches have addressed the 
potential of blocking TGF-β signal transduction, demonstrating that 
fibrogenesis may be counteracted 10. Nakao and coworkers used adenoviral 
overexpression of antagonistic Smad7 protein to inhibit TGF-β effects in 
fibroproliferative disease 11. In a similar approach Smad7 was generally 
overexpressed in the liver and effectively inhibited liver fibrogenesis 12. 
Notably, in most liver models it is assumed that the cell type most affected 
by treatment is the HSC, whereas in hepatocytes signaling and effects 
thereof have not been addressed thoroughly. Hepatocytes display TGF-β/R-
Smad signaling, which is associated with increased apoptosis rates 13.  
In the present study we wished to clarify the role of hepatocytes in the 
fibrotic liver response. Starting out from in vitro experiments with primary 
hepatocyte cultures and immortalized AML-12 cells, TGF-β signaling was 
assessed and apoptosis was found to be a minor effect. In a mouse model, 
hepatocyte-specific overexpression of Smad7 was achieved. Thereby the 
fibrogenic response after CCl4 intoxication was blunted. These results 
emphasize the dynamic nature of liver fibrosis, challenge the paradigm of 
HSC as crucial source for liver myofibroblasts and hint at a prominent 
profibrogenic role for hepatocytes. 
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Materials and Methods 
 
Materials 
Reagents and antibodies are listed in SupplTable1. 
 
Cell preparation and treatment 
AML12 cells, immortalized hepatocytes having retained typical hepatocyte 
features such as peroxisomes and bile canaliculi formation, expressing mRNA 
for Albumin, α1-antitrypsin, Transferrin, and gap junction proteins, were 
grown in complete medium (CRL-2254, ATCC). Cells were plated in 6-well 
plates (3x105cells/well) and starved for 6h (0.5%FBS) before addition of 
TGF-β. 
Hepatocytes were isolated from C57/BL-6 mice (male) S1* and plated on 
collagen coated 6-well plates (3x105cells/well) in Williams' mediumE 
supplemented with 10%FBS, 2mM L-glutamine, 1%penicillin/streptomycin, 
100nM dexamethasone. Medium was exchanged after 4h with Williams 
mediumE supplemented with 2mM L-glutamine and 1x 
penicillin/streptomycin and TGF-β was added as indicated.  
 
DNA laddering  
Genomic DNA degradation was analyzed as decribed S2. Briefly, primary 
hepatocytes stimulated either with TGF-β (5ng/ml) for 48h or a combination 
of TNF-α (10ng/ml) plus Actinomycin D (0.1 µM) for 24h and DNA was 
isolated by phenol/chlorophorm/isopropanol extraction. 20 µg DNA were 
loaded on a 1.5% agarose gel. 
 
Annexin-V staining 
Hepatocytes were plated on cover slips (80,000 cells/well). After over-night 
serum-starvation, cells were treated with 5ng/ml TGF-β or 10ng/ml TNF-
α/0.1µg/ml Actinomycin D. Residual culture medium was washed off the cells 
with PBS (2mM CaCl2). Cells were stained for 5 min with 0.25µg/ml Annexin-
V-Cy3 (Abcam) and 5 µg/ml Hoechst (Sigma) in PBS (2mM CaCl2). Unbound 
stain is washed off the cells with PBS (2mM CaCl2) and fluorescent signal is 
detected immediately. 
 
Immunofluorescence  
5x104 hepatocytes/AML12 cells per well were cultured on glass 8-well-
chamber slides (BD Biosciences, NJ, USA), fixed with acetone and stained as 
previously described S3.  
 
Transient reporter gene assays 
For luciferase reporter assays, AdCAGA9-MLP-Luc and PAI-1-Luc were used 
S4, 5. Luciferase activity was measured with Steady-Glo Luciferase (Promega, 
Madison, Wisconsin, USA) as described S6. 
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Northern blot analysis  
Northern hybridization was performed as previously described S7. 
 
Semiquantitative RT-PCR and quantitative real-time RT-PCR 
Total mRNA extraction, cDNA synthesis, RT-PCR and quantitative real-time 
RT-PCR were performed as previously described S8. A primer list is provided 
as SupplTable2. 
Briefly, total mRNA was extracted from cultured primary mouse hepatocytes 
and AML12 cells using the High Pure RNA isolation kit (Roche) and from liver 
tissue after homogenization in TRIZOL reagent (GIBCO BRL, Eggenstein, 
Germany; 1 ml/100 mg tissue). 
cDNA was synthesized from 1 µg RNA with the Transcriptor First Strand 
cDNA synthesis kit (Roche). One-step PCR was carried out with FastStart Taq 
DNA Polymerase, dNTPack system (Roche) and primers for Snail, E-
Cadherin, Claudin1, Integrinβ5, PAI-1, CTGF, TIMP-1, TSP-1 and Col1A1 as 
indicated in Suppl. Table 2. Albumin and rS6 (Ribosomal protein S6) mRNA 
were amplified as control.  
Quantitative real-time RT-PCR (qRT-PCR) was performed with the sequence 
detection system ABI Prism 7700 (Applied Biosystems) using TaqMan 
Universal PCR Master Mix, No AmpErase UNG (Part No. 4324018) and the 
following Gene Expression Assays: Smad7, Snail1, FN1, CTGF, Claudin1, 
Trombospodin1, Procollagen, type I, alpha 1, TIMP-1 and PAI-1. All reagents 
were purchased from Applied Biosystems. Samples were run in triplicate. As 
a house keeping gene, we investigated Peptidylprolyl isomerase A (PPIA). 
Levels of gene expression were determined by the comparative CT method 
(DDCT) for relative quantitation of gene expression. Relative quantification 
relates the PCR signal of the target transcript in a treatment group to that of 
another sample such as an untreated control. Real time quantitative RT-PCR 
was undertaken with 1 µg total RNA as previously described S8. 
 
Oligonuceotide microarray analysis 
3 independent hepatocyte preparations were stimulated with 5 ng/mL TGF-β 
for 1, 6 and 24h. Total RNA was purified with the RNeasy Mini kit® (Qiagen, 
Hilden, Germany). 5 µg RNA were transcribed into cDNA by oligo dT primers, 
reverse transcribed to biotinylated cRNA with the Gene Chip IVT® Labeling 
kit (Affymetrix, High Wycombe, UK) and hybridized to arrays of type 
moe430_2 from Affymetrix (Santa Clara, CA, USA). Microarray data were 
analysed with ANOVA using Micro Array Solution, version 1.0, from SAS (SAS 
Institute, Cary, NC, USA). Standard settings were used, except the following 
specifications: log-linear mixed models S9 were fitted for values of perfect-
matches, with constant treatment period and random array-id. 
Genes with mean expression changes greater than 1.5 fold (Log base 2 
greater than 0,5849625/-0,5849625) and P-values <0.05 were selected as 
significantly changed and classified according to Gene Ontology category 
"biological process" (annotation software DAVID). This microarray study 
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followed MIAME guidelines issued by the Microarray Gene Expression Data 
group. All files containing the raw data of the microarray analysis have been 
deposited to ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) at the 
European Bioinformatics Institute (Hinxton) and are publicly available.  
 
Immunoblot analysis 
Lysate preparations and Western blot analyses were performed as described 
S10. Briefly, 20 µg protein was separated by SDS PAGE (Bis-Tris Gel; 
NuPAGE, Invitrogen) and transferred to nitrocellulose membranes (Pierce, 
Rockford, IL). Non-specific binding was blocked with 5% milk in TBST for α-
SMA antibody (Sigma), phospho-Smad2, phospho-Smad3, Cleaved caspase-
3, PARP (Cell Signaling), Smad2, Smad3 (Zymed) and with 5% BSA Top 
Blocker (Fluka, No. 37766) for collagen type I antibody (Santa Cruz 
Biotechnology). Horseradish peroxidase linked goat anti-mouse, donkey anti-
goat (Santa Cruz) or swine anti-rabbit antibodies (DAKO Cytomation/P0217) 
were used as secondary antibodies. The membranes were developed with 
Supersignal Ultra (Pierce).  
 
Quantification of secreted TGF-β 
Serum free medium of cultured cells was replaced every 24h and stored at –
20°C. 4x104 MFB-F11 cells, cultured in DMEM supplemented with 10 % FCS 
and 15 µg/ml hygromycin B (96-well-plate) were serum starved overnight 
and stimulated with plain and acid activated (0.1 M HCl, neutralized with 
NaOH) culture supernatant as described S11. After 48h, 25 µl of the culture 
supernatant was transferred to a 96 well-plate. SEAP activity was measured 
with the Great EscAPeTM SEAP fluorescent detection kit at ex/em = 355/460 
nm. SEAP activity was normalized to total protein content of plated cells. 
 
Migration assay 
AML12 cells were seeded at 30% confluence in 6 well plates in complete 
medium with 10% FCS. 24h later, a scratch “wound” was introduced with a 
200 µl pipette tip (0h). After overnight serum starvation, the cells were 
(un)stimulated with TGF-β (5ng/ml) for 24h. Cell migration was assessed by 
phase contrast microscopy, comparing the width of the scratch at 0 and 24h.   
 
Generation of Smad7 transgenic mice  
A Flag-tagged mouse Smad7 cDNA fragment (1.3 kb) was generated by 
BamHI/XhoI restriction digestion of pcDNA3.1-Flag-Smad7 (provided by P. 
ten Dijke, Leiden University Medical Center). Sticky ends were blunted and 
cloned into the SmaI restriction site of the 8.2 kb U2 plasmid, which 
comprises 1.5 kb of CRP-promoter sequences, the 5´-cap site, CRP protein 
coding sequences from exons 1 and 2, intron 1 sequences as well as the 
3´polyadenylation signal (Fig5A S12). CRP-Smad7 transgenic mice were 
generated on an FVB background and phenotypised by PCR with CRP-sense 
(5’-AGACTGTATGAACAGAACAGTGG-3’) and Smad7–antisense (5’-
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GGACTCCAC GGCCTGAAG-3’) primers, generating a 550 bp amplification 
product.  
 
Genetically modified animals 
In addition to the CRP-Smad7 mice, two further genetically modified strains 
were investigated. That is, a double-transgenic mouse, in which based on a 
tetracycline-regulated system, expression of TGF-β1 can be regulated 
deliberately by addition or removal of doxycycline hydrochloride to the 
drinking water S13. Further, mice deficient in exon I of Smad7, leading to a 
partial loss of Smad7 function S14. 
 
CCl4 dependent chronic liver injury 
CRP-Smad7 transgenic and FVB wild type mice underwent i.p. injections of 
CCl4 3x/week for 8 weeks (0.5ml/kg, diluted 1:4 in mineral oil; Fig5C). 
Smad7 transgene expression was induced by i.p. injections of 10 µg LPS in 
PBS/25g weight (2x/week for 8 weeks; Fig5C). Sham-treated mice received 
mineral oil only. After 8 weeks, animals were killed 24 h after the last CCl4 
injection and liver samples were obtained.  
 
Serum enzymes and hepatic fibrosis indices 
500 µl blood was taken from anaesthetized mice for liver enzyme serum 
values. AST, ALT and AP values were determined with Calibrator Kit3 
(VITROS Chemistry Systems; Ortho-Clinical Diagnostics, Buckinghamshire, 
UK). Concentration of HA was determined with a Test Kit (Corgenix, 
Colorado, USA) at a wave-length of 450 nm using a Victor 1420 Multilable 
Counter spectrometer (Wallac, Wellesley, USA). Whole liver hydroxyproline 
content was determined as described S15. 
 
Liver histology and immunohistochemistry  
Liver specimen were fixed in 10% formalin and embedded in paraffin. 4 µm 
tissue sections were stained with hematoxylin-eosin for routine examination, 
or with picro-Sirius red for visualization of hepatic collagen deposition as 
described S16. All samples were scored simultaneously. Blinded to the study 
conditions, fibrosis was quantified from Sirius red-stained liver tissue 
sections by morphometric analysis with LEICA QWIN software (Solms, 
Germany). Presented values were the mean of ten fields (magnification, 
x100) taken from five liver sections per mouse. For α-SMA detection, a 
1:300 dilution of a mouse monoclonal anti-α smooth muscle actin antibody 
(SIGMA/A2547) was used. To detect phosphorylated Smad2, a 1:100 dilution 
of a rabbit polyclonal anti-PS2 antibody (3101; Cell Signaling) was used. 
Apoptosis and inflammation indices were quantified using immunostaining 
with antibodies to cleaved Caspase-3 (diluted 1:75) or CD43 (1:50) and 
subsequent processing of the sections with a standard horseradish 
peroxidase (HRP)-conjugated antibody system. Endogenous peroxidase was 
blocked with “peroxidase blocking reagent” (DAKO) for 30 minutes. 
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Peroxidase activity was shown with metal-enhanced diaminobenzidine (DAB) 
substrate (DAKO). Slides were counterstained with aqueous Mayers 
Hämalaun (1.09249.2500; Merck, Darmstadt, Germany), and then 
immunopositive cells were counted for cleaved caspase-3 and CD43 per 
observation field (10 fields per section, 200 fold magnification).  
Quantification of histological stainings was performed either by morphometric 
analysis with LEICA QWIN software (Solms, Germany) or calculating the 
relative number of positive cells (200 cells were evaluated per observation 
field). Presented values correspond to the means of ten fields (magnification, 
100x) taken from five liver sections per mouse of between 8 and 10 mice in 
total). 
 
Statistics 
Results are expressed as means ± standard error of the mean (SEM) and 
were analyzed either by Mann-Whitney test or by analysis of variance 
(ANOVA) followed by paired comparison, when appropriate. Statistical 
analysis of quantitative RT-PCR data was performed with Student’s t-test for 
paired data. A p value of lower than 0.05 was regarded significant.  
 
(* Reference S1-16, see Supplemental Materials.)
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Results 
 
A minority of hepatocytes undergo apoptosis in response to TGF-β 
TGF-β is considered pro-apoptotic for hepatocytes 14. However, careful 
investigation of cultured mouse hepatocytes indicates that only a minor 
fraction undergoes apoptosis in response to TGF-β, as assessed by Annexin-V 
staining (Fig1A), DNA laddering (Fig1B) and immunoblotting for active 
Caspase-3 and PARP degradation (Fig1C). Remarkably, hepatocytes are 
strongly responsive to TGF-β, as determined by R-Smad phosphorylation and 
(CAGA)9-MLP-Luc activation. TGF-β/ALK5 signaling is activated dose-
dependently and Smad2/3 phosphorylation is detected for at least 24h 
(Fig1D). (CAGA)9-MLP-Luc activation occurs within 4h over a wide TGF-β 
concentration range (Fig1E) and is about 10-fold higher than in HSCs (data 
not shown), indicating that hepatocytes are major target cells for TGF-β. To 
ascertain purity of cultured hepatocytes, we analyzed expression of HSC 
markers α-SMA and GFAP by RT-PCR, Western blot and immunofluorescence, 
all indicating few contaminating HSCs (<5%, Fig1F and FigSuppl1).  
These results prompted us to assess R-Smad phosphorylation in vivo in 
chronic liver damage. In CCl4-dependent liver fibrosis of mice and following 
bile duct ligation in rats, most hepatocytes were immunopositive for nuclear 
phospho-Smad2, whereas only few cells were positive for apoptosis marker 
“cleaved” Caspase-3 (Fig2A). A similar result was obtained in human liver 
biopsy samples from patients with chronic liver disease due to hepatitis B 
viral (HBV) or Schistosomiasis infection (Fig2B).  
 
Primary and immortalized hepatocytes loose their epithelial 
phenotype in response to TGF-β 
Epithelial cell layers maintain barriers to compartimentalize tissue. In 
epithelial monolayer cell cultures of hepatocytes or hepatocyte-like 
immortalized AML-12 cells, specialized structures such as gap-, adherens- 
and tight-junctions as well as desmosomes are detected. During culture of 
mouse hepatocytes, we observe a spontaneous morphological 
transdifferentiation from epithelial to a fibroblastoid phenotype within 48h 
under subconfluent conditions, indicating loose cell-cell contacts and loss of 
polarity. This is accelerated with TGF-β treatment (FigSuppl2A). The impact 
of TGF-β on fibroblastoid transdifferentiation was pronounced with AML-12 
cells (FigSuppl2B). 
Primary hepatocytes express and secrete TGF-β into the culture medium 
(FigSuppl2C, D), which may act autocrine/paracrine, thereby perpetuating 
the observed spontaneous phenotypic changes. Secretion of active TGF-β by 
hepatocytes increases during culture from 36pg (day1) to 520pg/mg total 
protein (day5). Total TGF-β levels are about 10 times higher than levels for 
active protein (FigSuppl2D). In line with this, intrinsic hepatocyte Smad2 
phosphorylation increases during cell culture (FigSuppl2E). 
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TGF-β target gene profiling in mouse hepatocytes 
To obtain a comprehensive view on TGF-β effects in hepatocytes, Affymetrix 
microarrays were performed. We aimed at detecting early (1h), intermediate 
(6h) and late (24h) target genes. Out of 39,000 transcripts present in the 
array, 761 were regulated by TGF-β greater than 1.5-fold (379 up- and 382 
downregulated; SupplTable3). Most genes were differentially expressed at 
intermediate and late time points.  
Consistent with previous studies 14, genes involved in apoptosis were found 
to be induced (e.g. GADD45-β, Bcl2 and Bim). Notably, genes participating in 
fibrogenesis and EMT were regulated (FigSuppl3A, SupplTable3). These 
comprise upregulated ECM components such as glycoprotein fibulin2, 
fibronectin and several collagen precursors, including collagen typeI, XV and 
XXVII. Integrin-β5, the receptor for fibronectin, was also induced. Transcript 
levels of proteins, which regulate turnover of these ECM proteins were 
differentially regulated, e.g., TIMP1 was increased, whereas MMP15 was 
down-regulated. Besides ECM components, pro-fibrogenic cytokines like 
PDGF, CTGF and TGF-β itself were induced.  
Inspection of genes associated with EMT revealed up-regulation of transcripts 
encoding for transcription factor Snail, that down-regulates E-cadherin 
expression. Similarly, tensin, which participates in cell migration and β-
catenin1 like protein are enhanced. Several cytoskeletal proteins necessary 
for pseudopod formation and cellular elongation during acquisition of 
mesenchymal morphology are up-regulated by TGF-β, including α-actinin1, 
gelsolin-like protein (Capg), coronin and keratin20.  At the same time, mRNA 
abundance of several genes involved in stabilisation of the cytoskeleton was 
markedly decreased, for example of desmoglein2, periplakin (both 
components of desmosomes) and profilin2. mRNA levels of ankyrin3, a 
protein that plays a role in the polarized distribution of many integral 
membrane proteins, as well as expression of basement cell membrane 
proteins, SPARC-related modular calcium binding1, collagen type IVα5 and 
collagen type XVIIIα1 were decreased.   
To validate microarray experiments, a set of the identified TGF-β target 
genes was assessed by real time qRT-PCR and Western blot. Representative 
results comprising E-cadherin, β-catenin, ZO-1, claudin-1, Snail, PAI-1, pro-
collagen type I(α1), TIMP1, TSP-1 and CTGF are presented as Fig4B,C. 
Overall, we determined a strong concordance between microarray values and 
RT-qPCR results for all tested genes. 
These data demonstrate that a differentiation process of hepatocytes into 
fibrogenic cells occurs, especially under the influence of TGF-β. 
 
AML-12 cells and mouse hepatocytes display fibroblastoid 
transdifferentiation in response to TGF-β 
Phosphorylation of R-Smad proteins as response to TGF-β generally occurs 
transiently, starting immediately after contact with the ligand, peaking 
between 1 and 3h, with subsequent degradation via the proteasome after 6h 
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15. In contrast, sustained C-terminal R-Smad phosphorylation was identified 
with mouse hepatocytes, as demonstrated for Smad2, in a time course 
experiment after challenge with TGF-β (FigSuppl4), indicating a long-term 
TGF-β response, previously identified as requirement for EMT in endothelial 
cells 16.  
TRITC-phalloidin staining of the F-actin cytoskeleton revealed epithelial 
architecture with intense membranous and diffuse or punctate cytoplasmic 
staining in AML-12 cells (FigSuppl3D). Treatment of AML-12 cells with TGF-β 
for 48h led to trans-differentiation from epithelial to fibroblastoid 
morphology, shifting epithelial architecture into a prominent fibroblastic 
organization of the F-actin cytoskeleton with distinct stress fibers emanating 
from newly formed focal adhesions. This morphological “transdifferentiation” 
was prevented by adding ALK-5 inhibitor SB431542 (FigSuppl3D). Due to 
spontaneous trans-differentiation of hepatocytes in monolayer culture, 
epithelial architecture was already partially lost at earlier time points in 
control mouse hepatocytes (cp. FigSuppl2A).  
Tight junctions are features of epithelial cells. They mediate cell-cell 
adhesions, regulate diffusion of small molecules across epithelial monolayers 
and maintain asymmetric distribution of proteins and lipids to apical and 
basolateral membrane domains. Expression and localization of the tight 
junction protein zonula occludens protein 1 (ZO-1) 17 occurs at the cell 
membranes of AML-12 cells. TGF-β stimulation led to loss of ZO-1 
membranous localization, while the cells gained a fibroblastic morphology 
(FigSuppl3D). Similar observations were made for adherens junction proteins 
E-cadherin and β-catenin. E-cadherin staining overlapped with phalloidin 
staining, which is in agreement with the established association of E-cadherin 
with the cortical F-actin cytoskeleton. In TGF-β treated cells, E-cadherin was 
absent in plasma membranes without cell-cell contact. Co-localization of E-
cadherin with F-actin stress fibers in trans-differentiated cells was not 
observed. From Western blot analyses, it was evident that E-cadherin was 
not only translocated from the cell membrane but also reduced in its 
expression (cp. FigSuppl3C). β-catenin performs dual roles as structural 
component of adherens junctions 18 and signaling molecule in the Wnt 
signaling pathway 19. Staining for β-catenin showed a similar distribution as 
seen with E-cadherin in the epithelial state. In TGF-β treated cells, the 
distribution of β-catenin was markedly altered, however nuclear localization 
was not seen, as would have been expected with activated Wnt signalling 
(FigSuppl3D). Furthermore, its expression level was unchanged 
(FigSuppl3C). 
Another feature of EMT is increased cell migration, which was evaluated by 
an in vitro wound healing assay. 24h after scratching an AML-12 monolayer, 
untreated cells exhibited increase of cell density with few cells migrating, 
whereas TGF-β treatment induced extensive migration (FigSuppl3E). 
Immunofluorescent co-stainungs for transferrin with F-actin or vimentin 
confirm the occurrence of intermediate stages during fibroblastoid 
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transdifferentiation of TGF-β treated mouse hepatocytes (FigSuppl3F). 
Hepatocyte origin of these cells is obvious, since beside transferrin positive 
staining, the morphology of contaminating HSCs can be easily discriminated 
(FigSuppl1). Further, profibrogenic behaviour of hepatocyte-derived 
fibroblasts was apparent as these cells coexpress collagen type I and 
cytokeratin18 (FigSuppl3F, FigSuppl5).    
 
 
Hepatocyte transdifferentiation occurs in vivo immediately adjacent 
to fibrotic lesions  
To proof in vivo relevance, we examined Snail, a transcription factor that 
downregulates E-cadherin, thus representing a typical marker for EMT. In 
liver samples of HBV patients, hepatocytes with nuclear staining for Snail 
were observed in damaged regions (Fig3A), whereas control liver samples 
were negative for Snail expression. Similarly, liver sections from mice with 
CCl4-induced fibrosis and rats with bile duct ligation display nuclear Snail 
staining in hepatocytes located around injured areas (not shown). To 
highlight the impact of TGF-β for Snail induction in hepatocytes in vivo, we 
examined a double-transgenic mouse model, in which the expression of TGF-
β can be regulated deliberately by doxycycline 20. In induced mice, TGF-β 
plasma levels reach values ranging from 250 to 1,200 ng/ml, being 10 to 30 
times above normal. These mice spontaneously develop liver fibrosis. 
Immunohistochemical analysis revealed nuclear phospho-Smad2 staining in 
hepatocytes, indicating activated TGF-β signaling (not shown). In parallel, 
hepatocytes with nuclear staining for Snail appear (Fig3A), suggesting a 
direct link between TGF-β signaling and Snail expression in vivo.  
Since transferrin is regarded a specific marker for hepatocytes, sections of 
injured liver regions from HBV patients were stained for Snail and transferrin. 
These stainings suggest that at the border of inflamed regions with 
significant scar formation, cells at the same time express transferrin and 
have lost regular epithelial cell like cell-cell interconnections and polarity 
(Fig3B). These hepatocytes may have undergone partial EMT, which is 
underlined by the high percentage of cells with nuclear Snail expression in 
the same area. Of note, there are Snail positive cells lacking transferrin, 
putatively in a later transition stage or originating from infiltrating cells. 
Further, immunofluorescence co-staining for transferrin and collagen type I 
indicates occurrence of partially transdifferentiated hepatocytes (about 50% 
of the remaining hepatocytes in damaged regions) and supports a 
profibrogenic role of liver parenchymal cells.  
 
Smad7 inhibits TGF-β-induced profibrogenic gene expression in 
hepatocytes   
Smad7 is efficient as antagonist of TGF-β-dependent R-Smad activation and 
downstream signaling. Thus, we tested the effect of Smad7 expression in 
mouse hepatocytes on (partial) EMT- and fibrogenesis-related outcomes. 
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Smad7 expression blunted TGF-β-dependent Smad2 phosphorylation (Fig4A) 
and activation of (CAGA)9-MLP-Luc (Fig4B). Smad7 expression abrogated 
TGF-β induction of tested EMT- and fibrogenesis-related genes, e.g., PAI-1, 
Snail, CTGF and type I collagen (Fig4A, B). To morphologically visualize the 
impact of Smad7/TGF-β on hepatocyte transdifferentiation, we imaged ZO-1 
by immunofluorescence. TGF-β-induced loss of cell-cell contacts was blunted 
with SB431542 addition or Smad7 expression indicating participation of ALK-
5/R-Smad signaling (Fig4C). Thus, Smad7 attenuates profibrogenic TGF-β 
signaling and (partial) EMT in hepatocytes in vitro.  
 
Blunting TGF-β signaling in hepatocytes reduces CCl4-dependent liver 
damage and fibrogenesis 
To experimentally test the role of hepatocytes and to specifically address the 
relevance of TGF-β signaling in this cell-type during fibrogenesis in vivo, a 
transgenic mouse was created, in which Smad7 is inducibly expressed in 
hepatocytes. A construct harbouring the C-reactive protein (CRP) promoter, 
previously generated to express TGF-β in hepatocytes 21 was utilized. The 
TGF-β cassette was exchanged by murine Flag-Smad7 to obtain the targeting 
vector (Fig5A). The CRP promoter is activated by acute phase responses, 
e.g. with liver damage, LPS stimulation and by cytokines of the interleukin 
(IL) family. Functionality and cell-type specific trans-activation of the 
promoter was tested by transient transfection of HepG2 cells and CFSC, a 
cell line representing activated HSCs. Cells were stimulated with LPS, IL-6 
and a combination of IL-1, IL-6 and LPS. All challenges induced Smad7 
protein expression in HepG2 cells, as determined by Western blot analysis, 
whereas CFSC were unresponsive (Fig5B).  
 
In the following, an experimental liver injury model was chosen. CCl4 
treatment, causing necroinflammatory liver injury followed by a chronic 
repair response, represents a model of general hepatotoxicity. CRP-Smad7 
transgenic mice (S7tg) and FVB control mice were treated over the whole 
investigation period of 8 weeks with LPS, CCl4, a combination of both, or 
were left untreated (Fig5C) and the effect of hepatocyte-specific Smad7 
expression on liver damage and fibrogenesis was analyzed after sacrifice at 8 
weeks. LPS-dependent induction of transgene expression was observed with 
RT-PCR analysis, identifying a 550 bp amplification product (Fig5D) and by 
immunoblotting for the Smad7 attached Flag tag (Fig5E, F). By IHC, positive 
staining with an anti-Flag antibody is observed in hepatocytes with strongest 
transgene expression in periportal regions (Fig6A). In serial sections, HSCs 
were stained with antibodies for α-SMA (Fig6A, FigSuppl6) and GFAP (not 
shown), indicating that Flag-positive staining is restricted to hepatocytes. In 
FVB wild-type mice, CCl4 application significantly induced TGF-β signaling, as 
determined by phospho-Smad2 analysis with Western blot (Fig5F) and IHC 
(Fig6A). LPS-dependent R-Smad activation was only weak (Fig5F, Fig6A) 
compared to CCl4. Ectopic expression of Smad7 after LPS challenge blunted 
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CCl4-induced R-Smad activation (Fig5F, Fig6A). CCl4 intoxication induced 
extensive septa formation with some nodules in FVB wild-type mice. 
Numerous indicators for fibrosis were significantly reduced in CCl4 treated 
S7tg mice after transgene induction. 8 weeks CCl4-treated FVB wild-type 
mice had about 2.5-fold increased interstitial collagen deposition compared 
to Smad7 expressing mice, as determined by Sirius red staining and 
morphometric quantification (Fig6B). The number of activated HSCs was also 
decreased in LPS-induced S7tg mice as assessed by α-SMA staining (Fig6B). 
Western blot analysis of liver lysates from these mice accordingly display the 
weakest α-SMA signal (Fig5F).  
Further, liver inflammation was analysed in CCl4 intoxicated wild-type and 
S7tg mice by identifying CD43-positive infiltrating mononuclear cells and 
lymphocytes, mainly observed at pericentral areas. Ectopic expression of 
Smad7 in hepatocytes markedly decreased the number of CD43 positive cells 
(30±6 vs 14±3 positive cells per field; FigSuppl7). In addition, 
overrepresentation of Smad7 protein led to a significantly decreased number 
of apoptotic cells in CCl4 damaged liver, as measured by IHC using an 
antibody for cleaved Caspase-3 (FigSuppl7). 
The inflammatory grade and fibrotic stage of the diseased livers were 
evaluated using the Scheuer scoring system (Fig6C), revealing better 
outcome in animals with hepatocyte Smad7 expression.  
In line with this, the extent of liver injury after CCl4 intoxication, assessed by 
the release of hepatocyte-specific enzymes ALT, AST, AP and HA into serum, 
was reduced in LPS treated S7tg mice when compared to FVB wild-type mice 
(Table1 and FigSuppl8). Finally, Col1A1 mRNA (Fig6D) and Col1A2 protein 
expression (cp. Fig5F) as well as hydroxyproline content (Fig6E) were lower 
in animals with Smad7 overexpressing hepatocytes.  
To further confirm a link between Smad7 expression levels and hepatocyte 
transdifferentiation in vivo, we investigated Snail expression by IHC in two 
animal models after CCl4 injury. The number was decreased in Smad7 
transgenic mice and markedly elevated in mice with disrupted Smad7 
expression due to mutations within the gene locus (Fig6F).  
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Discussion 
 
In current concepts on liver fibrogenesis, non-parenchymal cells are 
pacemakers, participating in all key regulatory events orchestrating the 
profibrogenic response following parenchymal injury. Most studies in the last 
decade have focused on HSCs and analyzed characteristic features like 
plasticity and trans-differentiation to myofibroblasts, a phenotype that can be 
readily recapitulated in tissue culture. Activated HSCs proliferate and express 
the intermediate filament α-SMA and profibrotic genes 2. Further, liver 
myofibroblasts stand for a wide repertoire of functions that emphasize the 
dynamic nature of the wound-healing response, including synthesis of fibrillar 
collagens, contractile and migratory activities, secretion of chemotactic and 
vasoactive factors, and the secretion of MMPs and TIMPs.  
The origin of myofibroblasts in the injured liver is now under scrutiny, 
although evidence hints at HSCs as major source. Complexation of this 
simplified view comes from recent studies aimed at monitoring the 
expression of type I collagen and α-SMA in a dual reporter transgenic mouse, 
indicating functional differences between periportal myofibroblasts shown to 
express collagen I but not α-SMA and myofibroblasts derived from HSCs, 
which express both components 22. Moreover, HSCs from these transgenic 
mice display a day-to-day variation in expression of genes regarded as 
marker proteins for the myofibroblast phenotype. Studies with animals and 
human tissue indicate that bone marrow stem cells infiltrate the liver and 
contribute to the myofibroblast population after damage. This may occur 
directly or through an intermediary cell, such as quiescent HSCs or CD45+ 
fibrocytes 22, 23. Another source may be portal fibroblasts that are described 
in fibrotic diseases with a portal component, e.g. viral hepatitis and 
autoimmune conditions 24. In coherence with our data on hepatocytes, TGF-
β, besides mechanical tension, is required for myofibroblast 
transdifferentiation of this cell type 25.  
Hepatocyte apoptosis is regarded as potent profibrogenic stimulus. In rat 
hepatocytes, it was shown that TGF-β may induce apoptosis 26. This finding 
was strengthened by in vivo data with transgenic animals overexpressing 
TGF-β specifically in hepatocytes under the control of the albumin promoter, 
where besides proliferative activity and fibrosis, apoptosis was observed in 
dependency of this cytokine 27.  
Our data in principle confirm these findings. However, they indicate that 
apoptosis is a fate that only a minority of hepatocytes (~5%) undergo. 
Arguably, the extent of apoptotic hepatocytes upon TGF-β may differ 
depending on nature and timing of injury, both in artificial in vitro systems as 
well as in experimental models or tissue from diseased patients. Our results, 
however, impressively confirm that most hepatocytes are responsive to TGF-
β. Pronounced R-Smad activation was detectable over more than 20h in vitro 
and revealed a similar strong response to TGF-β in hepatic diseases as well 
as in transgenic mice with inducible TGF-β expression. 
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To get a clue at effects that TGF-β exerts on hepatocytes, we performed 
gene expression profiling. Transcriptional regulation of a set of important 
profibrogenic mediators, including PDGFs, IL-15, TIMP-1, MMP-9, EGFR and 
several collagens was observed. Hepatocytes were able to express and 
secrete CTGF in response to TGF-β 28, which suggests paracrine effects of 
hepatocytes on other cell-types and especially may contribute to HSC 
activation. We chose to specifically intervene in hepatocyte TGF-β signaling 
in a mouse model with transgene expression guided by the CRP promoter. In 
these animals, CCl4 was applied for 8 weeks to induce liver fibrosis and was 
combined in some groups with LPS, to stimulate transgene expression. 
Hepatocyte-specific Smad7 overexpression was sufficient to reduce liver 
damage, as assessed by fibrotic stages and inflammatory grades.  
These results provide evidence for plasticity of the hepatocyte phenotype, 
which was originally related to morphogenesis, epithelial repair and tumor 
invasiveness only. Just recently, changes of epithelial cell phenotype was 
associated with fibroproliferative diseases 3. It is suggested that a substantial 
number of organ fibroblasts appear through a reversal of epithelial cell fate 
under pathologic conditions. In kidney disease, EMT is established as 
pathomechanism for renal fibrosis, triggered by TGF-β in renal tubular 
epithelial cells, leading to a substantial increase in the number of 
myofibroblasts 3.  
Epithelial cell ransdifferentiation comprises alterations in cellular morphology 
characterized by changes in cell polarity and loss of adhesion protein 
expression. TGF-β can initiate and maintain this process in a variety of 
biological systems and pathophysiological contexts by activating major 
signaling pathways and transcriptional regulators integrated in extensive 
cellular networks 29. In MDCKII cells, claudin-1, claudin-2, occludin, and E-
cadherin disappear within 72h of exposure to TGF-β. It is suggested that this 
expression loss occurs through a Smad-independent mechanism, involving 
MEK and PI3K pathways with expression of Snail. On the other hand, a 
complete loss of E-cadherin and transition to the mesenchymal phenotype 
additionally requires Smad signaling, which results in formation of β-
catenin/LEF-1 complexes that induce EMT 30. Participation of TGF-β in the 
regulation of Notch signaling has been reported previously at the onset of 
EMT in epithelial cells from mammary gland, kidney tubules, and epidermis 
32. A set of the above mentioned genes and others described to be involved 
in EMT - including Snail and Notch2 - were identified as TGF-β target genes 
in hepatocytes. Our data on hepatocyte plasticity are supported by recent 
findings, showing upregulation of α1(I) collagen mRNA expression and type I 
collagen deposition in mouse hepatocytes and AML-12 cells as a result of 
Smad2/3/4-dependent induction of Snail-1 33, 34.  
From in vivo genetic lineage tracing studies it is suggested that up to 40% of 
resident fibroblasts may result from hepatocyte transdifferentiation and EMT 
in liver fibrosis 35. It is difficult to quantify the abundance of 
transdifferentiated hepatocytes in our in vivo studies, as 
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immunohistochemistry indicates that several transition states exist. Thus, 
our data put forward the notion that Smad7 overexpression in hepatocytes 
inhibits (partial) EMT as exemplified by reduced Snail expression. 
In summary, our data provide in vitro and in vivo evidence that profibrogenic 
TGF-β functions during liver damage are also directed toward hepatocytes. A 
TGF-β-induced gene expression profiling of hepatocytes indicates a minor 
role of apoptosis and induction of fibrogenesis- and EMT-related genes. While 
the definite occurrence of EMT in this cell type in vivo needs further proof, 
e.g. by double transgenic animals expressing fluorescent proteins under the 
control of hepatocyte and myofibroblast specific promoters, our results 
suggest that hepatocytes and TGF-β signaling in this cell type play a 
prominent role for fibrogenesis.  
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Figure Legends 
 
 
Figure 1. TGF-β induction of apoptosis in vitro and in vivo. (A) Hepatocytes 
were serum starved overnight and (un)treated with 5 ng/ml TGF-β or 
10ng/ml TNF-α and 0.1 µg/ml Actinomycin as indicated. Cells were stained 
with Annexin-V-Cy3 for apoptosis (red) and Hoechst for nuclei. Only few cells 
become apoptotic upon TGF-β. (B) DNA laddering and (C) Western blot 
analysis of Caspase 3 and PARP cleavage products confirm this result. (D, E) 
TGF-β signaling in hepatocytes - (D) Immunoblot of Smad2 and 3 
phosphorylation after dose- and time-dependent TGF-β stimulation in mouse 
hepatocytes. β-actin served as loading control. (E) Hepatocytes were 
infected with adenoviruses containing several copies of a Smad3/4 binding 
element, driving luciferase expression, (CAGA)9-MLP-Luc, and stimulated 
with increasing concentrations of TGF-β (0.5 - 10 ng/ml). Luciferase activity 
was quantified 4 hours later. (F) Purity of hepatocyte cultures was 
demonstrated: RT-PCR analysis of hepatocyte- (albumin, transferrin) and 
HSC-marker genes (α-SMA, GFAP) using total RNA lysates; α-SMA protein 
expression was tested in protein lysates from hepatocytes; HSCs were used 
for positive control lanes; mouse hepatocytes were cultured on glass slides 
for 1 day and immunostained for glial fibrillary acidic protein (GFAP,1:100). 
Only some single cells stained positive, representing ~3% of total cell 
number. 
 
Figure 2. TGF-β signaling and apoptosis were analyzed by IHC in (A) mouse 
liver chronically injured by 8 week CCl4 treatment, in damaged rat liver after 
2 weeks bile duct ligation (BDL), and (B) in patients with chronic liver 
disease from hepatitis B virus (HBV) or Schistosomiasis infection. Nuclear P-
Smad2 was detected in nearly all hepatocytes, whereas Caspase-3 
expression was marginally observed.  
 
Figure 3. Hepatocytes in injured liver express Snail and disperse from 
epithelial interconnections. (A) Immunolocalization of Snail expression in 
liver from healthy and HBV infected patients and from mice (un)induced to 
express active TGF-β by a transgene 36. (B) Transdifferentiated hepatocytes 
– Top, Sections from HBV patients were co-immunostained for Snail and 
transferrin, indicating that transferrin-positive cells (green; Alexafluor633 
goat anti rabbit, Molecular probes) start to express Snail (red; Alexafluor546, 
goat anti rabbit) and disperse from epithelial interconnections. Bottom, Co-
immunostaining for collagen type I (green) and transferrin (red) in liver 
tissue from healthy and HBV infected patients, examined by confocal 
microscope. Quantification was performed by counting cells with positive 
staining in damaged regions (5 observation fields from 4 different HBV 
patients); +, positive staining; Tf, transferrin; Tf/Col+, transferrin and 
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collagen positive; Tf/Snail+, transferrin and Snail positive; ** indicates 
P<0.01. 
 
Figure 4. Smad7 blunts profibrogenic TGF-β signaling and partial EMT in 
hepatocytes. Mouse hepatocytes were infected with adenoviruses harbouring 
LacZ or Smad7 sequences and treated with TGF-β (5ng/ml; 24h). (A) WB 
analysis of Smad7 expression and its impact on Smad2 
phosphorylation/CTGF expression. (B) Smad7 effect on reporter gene 
activation of the PAI-1 promoter, (CAGA)9–MLP-Luc, Snail mRNA and type I 
procollagen mRNA expression in mouse hepatocytes. (C) Immunofluorescent 
staining of cultured hepatocytes for ZO-1 reveals that TGF-β-dependent loss 
of cell-cell contacts is abolished by SB431542 and Smad7. 
 
Figure 5. Ectopic Smad7 expression in hepatocytes is sufficient to blunt liver 
fibrogenesis in mice after CCl4 intoxication. (A) Simplified Smad7 expression 
cassette for transgenic mouse generation; CRP, C-reactive protein; a more 
detailed description is found in Materials and Methods and by Kanzler et al. 
21; (B) Smad7 transgene expression after transient transfection of CFSC and 
hepatocytes (HCs) versus positive control lysate with Smad7 overexpression 
after infection with AdSmad7 (S7C). Lysates were prepared without 
challenge or after stimulation with LPS, IL-1, IL-6 and combinations thereof. 
Only hepatocytes are induced for transgene expression, indicating cell-type 
specificity. β-actin was used as loading control. (C) Scheme of animal 
treatment protocol. Animals underwent the same weekly treatment during 8 
weeks; tissue and serum samples were taken after 8 weeks. (D, E) In vivo 
quantification of Smad7 transgene expression in response to LPS by RT-PCR 
(D) and Western blot analyses (E) of liver tissue. FVB, mouse strain without 
transgene; S7tg, Smad7 transgenic mouse; pU2-Flag-Smad7: plasmid 
harbouring the expression cassette; the 218 bp product represents an 
amplification product indicating mouse CSRP2 gene expression, which occurs 
constitutively in mouse tissue and was therefore used as control for the PCR 
reaction. (F) Liver protein lysates of control mice (FVB) and transgenic 
animals (S7tg) exposed to CCl4 and/or LPS, as indicated, were examined for 
Smad2 phosphorylation, α-SMA and Col1A2 expression by immunoblotting. 
Blots were reprobed with anti-β-actin as loading control. 
 
Figure 6. Hepatocyte specific expression of Smad7 inhibits liver fibrogenesis 
and partial EMT in mice with CCl4 induced liver damage.  (A) Top - Flag and 
α-SMA were stained in serial sections to document hepatocyte specific 
expression of transgenic Smad7. (A Bottom, B) Representative 
photomicrographs of mouse liver sections from FVB and S7tg strains 
(un)treated according to the protocol (Fig.7C) and stained for markers of 
fibrosis and damage (p-Smad2 collagens (sirius red) and α-SMA) as indicated 
are shown. Quantification was performed by morphometry. (C) Inflammatory 
grade and fibrotic stage of mouse liver tissues were evaluated according to 
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the Scheuer system based on the above quantitative data. (D) Real time RT-
PCR analysis of α-1 procollagen I mRNA. (E) spectrophotometrical analysis 
(Pharmacia Biotech, Ultraspec 2000; OD 558 nm) of hydroxyproline content, 
as a measure for the degree of fibrosis. (F) IHC and quantification of Snail 
expression in WT, S7tg and mice with a disrupted Smad7 gene (S7ΔE1) after 
8 weeks of CCl4 and LPS treatment. Quantification of IHC was performed with 
8-10 animals per group as described in SupplMaterials. 
 
 
